A new Neuron study reports blocking the action of the mTORC1 protein causes mice to stop problem drinking behaviors. The findings could help develop new treatments for addictive behaviors in people.
Study implicates disrupted autophagy and protein aggregation in the pathogenesis of autism schizophrenia and social behavior deficits in other disorders.
Researchers note reduced fear and stress responses following a mildly traumatic event when rapamycin, a protein synthesis blocker, is administered.
Rapamycin, a drug approved for the treatment of cancer and transplant patients increases amyloid-beta protein plaques in the brains of mice.
According to a new study, an FDA approved drug prevented the development of Parkinson's disese in mice genetically engineered to develop the neurodegenerative disorder.
Researchers are testing whether low doses of Rapamycin, a drug most commonly used as an immunosuppressant following an organ transplant, can help to prevent Alzheimer's disease.
Mutations of the PTEN gene cause neurons to grow to twice the size and form four times the number of synaptic connections to other neurons as a normal neuron. Removing the RAPTOR gene, an essential gene in the mTORC1 signaling pathway, prevents the neuronal and synaptic overgrowth associated with PTEN mutations. Using Rapamycin to inhibit mTORC1 recues all the changes in neuronal overgrowth.
Researchers investigate how neurons are generated in hope to find potential new treatments for TSC and other neurological disorders.